title: Potent HIV-specific responses are enriched in a unique subset of CD8+ T cells that coexpresses CD4 on its surface.
abstract: In humans, approximately 3% of peripheral CD8+ T cells coexpress CD4 dimly on their surface and hence are designated as CD4(dim)CD8(bright) T cells. We evaluated the contribution of this CD4(dim)CD8(bright) T-cell population to anti-HIV immunity. We demonstrate that CD4(dim)CD8(bright) T cells generate greater than 55% of CD8+ T-cell antigen recognition and effector response to HIV, as evaluated by multiple parameters for assessing T-cell antiviral immunity, including HIV tetramer recognition, cytokine production, and cytolytic potential. Inhibition of major histocompatibility class II (MHC-II) on target cells or CD4 on CD4(dim)CD8(bright) T cells diminishes their anti-HIV responses, suggesting that CD4 on effector cells and MHC-II on target cells provides an additional arm of contact between effector and target cells which is critical to CD4(dim)CD8(bright) T-cell function. CD4(dim)CD8(bright) T cells also exhibit features that are indicative of central memory T cells. Finally, CD4(dim)CD8(bright) T cells are elevated in blood of HIV+ long-term nonprogressors in comparison to HIV- donors. Collectively, our findings show that CD4(dim)CD8(bright) T cells designate an enriched antiviral subpopulation of CD8+ T cells that should be targeted for therapeutic intervention or evaluation of vaccine efficacy.
authors.affiliation: Department of Immunology/Microbiology, Rush University Medical Center, Chicago, IL 60612, USA.
authors.forename: Andrew
authors.initials: A
authors.lastname: Zloza
authors.forename: Jason M
authors.initials: JM
authors.lastname: Schenkel
authors.forename: Allan R
authors.initials: AR
authors.lastname: Tenorio
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Martinson
authors.forename: Paul M
authors.initials: PM
authors.lastname: Jeziorczak
authors.forename: Lena
authors.initials: L
authors.lastname: Al-Harthi
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology / Q000627:therapeutic use; D000328:Adult; D015704:CD4 Antigens / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D005260:Female; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control; D015497:HIV-1 / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D016915:AIDS Vaccines; D015704:CD4 Antigens; D000949:Histocompatibility Antigens Class II
references.citation: Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3794-9
references.pmid: 15731353
references.citation: Immunology. 2001 Jul;103(3):270-80
references.pmid: 11454056
references.citation: Blood. 2002 Jan 1;99(1):207-12
references.pmid: 11756173
references.citation: J Virol. 1998 Nov;72(11):9054-60
references.pmid: 9765450
references.citation: Eur J Immunol. 2006 Mar;36(3):583-92
references.pmid: 16506292
references.citation: Biochem Biophys Res Commun. 1993 Mar 15;191(2):601-9
references.pmid: 8461016
references.citation: Blood. 2004 Jul 15;104(2):478-86
references.pmid: 15044252
references.citation: J Clin Immunol. 1993 Mar;13(2):113-8
references.pmid: 8100570
references.citation: J Neurol. 1989 Sep;236(6):329-35
references.pmid: 2571681
references.citation: J Exp Med. 2007 Oct 1;204(10):2473-85
references.pmid: 17893201
references.citation: Blood. 2006 Jun 15;107(12):4781-9
references.pmid: 16467198
references.citation: FASEB J. 2006 May;20(7):982-4
references.pmid: 16571772
references.citation: J Clin Invest. 1991 Apr;87(4):1462-6
references.pmid: 1707063
references.citation: J Leukoc Biol. 2006 Jan;79(1):4-6
references.pmid: 16380600
references.citation: Cell Immunol. 1993 Jul;149(2):376-89
references.pmid: 8101138
references.citation: Proc Natl Acad Sci U S A. 2005 May 17;102(20):7239-44
references.pmid: 15872023
references.citation: Immunogenetics. 1985;21(3):235-46
references.pmid: 3872841
references.citation: J Immunol. 2004 May 15;172(10):6407-17
references.pmid: 15128832
references.citation: J Immunol Methods. 2003 Oct 1;281(1-2):65-78
references.pmid: 14580882
references.citation: Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8727-32
references.pmid: 15173593
references.citation: J Immunol. 2005 Mar 1;174(5):2612-8
references.pmid: 15728467
references.citation: Science. 1998 Mar 27;279(5359):2103-6
references.pmid: 9516110
references.citation: J Virol. 2004 Feb;78(3):1160-8
references.pmid: 14722271
references.citation: Clin Exp Immunol. 1985 Apr;60(1):55-60
references.pmid: 3874016
references.citation: Vet Immunol Immunopathol. 1999 Dec 15;72(1-2):55-66
references.pmid: 10614493
references.citation: Springer Semin Immunopathol. 2006 Nov;28(3):209-19
references.pmid: 16932955
references.citation: Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3111-6
references.pmid: 9501224
references.citation: J Exp Med. 1998 Apr 6;187(7):1139-44
references.pmid: 9529330
references.citation: J Immunol. 1985 Apr;134(4):2281-6
references.pmid: 2982943
references.citation: Leukemia. 1998 Apr;12(4):499-504
references.pmid: 9557607
references.citation: Cytometry. 1994 Mar 15;18(1):35-41
references.pmid: 8082485
references.citation: Scand J Haematol. 1985 Aug;35(2):233-9
references.pmid: 3876598
references.citation: Blood. 2003 Sep 15;102(6):2156-64
references.pmid: 12791668
references.citation: Annu Rev Immunol. 2004;22:745-63
references.pmid: 15032595